In:
The Neurologist, Ovid Technologies (Wolters Kluwer Health), Vol. 28, No. 4 ( 2022-12-26), p. 270-272
Abstract:
Cerebral vasculitides are often devastating conditions that require immediate diagnosis and treatment. Case report: We report a pathologically proven clinical case of primary central nervous system vasculitis in a 50-year-old man with a diagnosis of relapsing-remitting multiple sclerosis after alemtuzumab therapy, which required additional immunosuppression to control this life-threatening condition. Conclusion: In patients presenting subacute neurological deterioration after alemtuzumab therapy, primary central nervous system vasculitis should be considered as a differential diagnosis among other autoimmune conditions.
Type of Medium:
Online Resource
ISSN:
2331-2637
DOI:
10.1097/NRL.0000000000000480
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2022
detail.hit.zdb_id:
2070987-0
Bookmarklink